Login to Your Account

QLT Beginning Two Phase III Trials Of Xenova Cancer Drug

By Randall Osborne

Monday, July 1, 2002
Almost a year after in-licensing the P-glycoprotein membrane inhibitor tariquidar from Xenova Group plc, QLT Inc. said it is starting two Phase III trials to explore the drug's use as an adjunct with first-line chemotherapy in non-small-cell lung cancer (NSCLC). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription